68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma Clinical Trial

Official title: An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC

Status Terminated

Clinical Trial Summary

This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To substitute 68Ga-DOTATOC for 111In-pentetreotide on an expanded access basis, in tumor imaging for study subjects, where the care provider believes that somatostatin imaging is clinically indicated, until such time as 68Ga-DOTATOC becomes commercially available.

SECONDARY OBJECTIVES:

I. To gain experience in the utility of 68Ga-DOTATOC in the management of neuroendocrine tumors at The University of Texas M.D. Anderson Cancer Center (MDACC).

II. To acquire proficiency in generating 68Ga-DOTATOC for human use at MDACC.

OUTLINE:

Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.

After completion of study, participants are followed up at 24 hours or within 72 hours, and at 30 days. ;

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Meningioma
• Metastatic Well Differentiated Neuroendocrine Neoplasm
• Multiple Endocrine Neoplasia
• Multiple Endocrine Neoplasia Type 1
• Neoplasms
• Neuroendocrine Neoplasm
• Neuroendocrine Tumors
• Somatostatin Positive Neoplastic Cells Present
• Von Hippel-Lindau Disease
• Von Hippel-Lindau Syndrome

• NCT number: NCT03001349
• Study type: Interventional
• Source: M.D. Anderson Cancer Center
• Status: Terminated
• Phase: Early Phase 1
• Start date: May 16, 2017
• Completion date: February 5, 2021